Article

Santen CEO joins OccuLogix board

Napa, CA—Santen Inc.'s president and chief executive officer, Adrienne L. Graves, PhD, has joined the OccuLogix Inc. board of directors.

Before she became president in 2002, Dr. Graves was vice president of clinical affairs for Santen and helped to move three ophthalmic products through the FDA approval process. Prior to her work with Santen, Dr. Graves worked for Alcon Laboratories Inc.

Elias Vamvakas, OccuLogix's chairman and chief executive officer, said the company would benefit from Dr. Graves' involvement in the clinical, regulatory, and commercial development of the RHEO procedure.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.